Serlopitant is an oral NK1R antagonist that has undergone phase II testing to treat itch related to AD; however, the change in WI-NRS scores in the treatment group was not significantly different from that in the placebo group (NCT02975206). This evidence concerns the gene TACR1 and Alzheimer disease.